FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
2020 · Clinical Cancer Research · 160 citations
https://doi.org/10.1158/1078-0432.ccr-20-3652
X
Xinyuan Zhang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
209
Papers
5.2K
Citations
44
h-index
90
i10-index
Xinyuan Zhang is an academic researcher from Jiangxi University of Traditional Chinese Medicine. The author has contributed to research in topics: Pharmacogenetics and Drug Metabolism & Drug Solubulity and Delivery Systems & Lung Cancer Treatments and Mutations. The author has an h-index of 44, co-authored 178 publications.
ORCID: 0000-0002-4636-1202Papers by this author
worksPeptides, new tools for plant protection in eco-agriculture
2023 · Advanced Agrochem · 112 citations
https://doi.org/10.1016/j.aac.2023.01.003
PGC-1α promotes mitochondrial respiration and biogenesis during the differentiation of hiPSCs into cardiomyocytes
2020 · Genes & Diseases · 40 citations
https://doi.org/10.1016/j.gendis.2020.12.006
NRF2 is required for structural and metabolic maturation of human induced pluripotent stem cell-derived ardiomyocytes
2021 · Stem Cell Research & Therapy · 31 citations
https://doi.org/10.1186/s13287-021-02264-2
Modulating the tumoral SPARC content to enhance albumin-based drug delivery for cancer therapy
2024 · Journal of Controlled Release · 31 citations
https://doi.org/10.1016/j.jconrel.2023.12.057
In vitro digestion of tofu with different textures using an artificial gastric digestive system
2022 · Food Research International · 27 citations
https://doi.org/10.1016/j.foodres.2022.111458
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat